RAVENSBURG, Germany — Vetter said it has reached several key development and launch milestones for V-OVS® next, its next-generation tamper-evident syringe closure system, as the company moves the product closer to commercialization.
The globally operating contract development and manufacturing organization said the updated closure system was developed based on extensive market feedback and features improvements in handling, functionality, and design. Vetter said the system is designed to fit a wide range of syringe formats and to enhance protection and usability across applications including ophthalmology, aesthetic injectables, diluents, and biologics. The product was unveiled at PharmaPack 2025 and has since progressed through multiple steps toward commercial readiness, with launch targeted for 2027.
Following a multi-cycle development process, Vetter said it has finalized the design of V-OVS® next and begun preparations for industrialization. As part of that effort, the company will supply its primary syringe glass partners with NFHU materials to support further implementation and testing across various syringe formats.
“With the first biopharma customers already giving positive feedback, we’re excited to see market uptake by some glass suppliers,” said Lars Hahn, Senior Vice President Global Sales Organization at Vetter. “We’ve already had successful conversations with multiple value chain partners and received consistently encouraging responses that reinforce our confidence in this launch.”
Vetter also reported completing additional verification activities, including a second Human Factors study and a key Functional Study, both of which produced positive results. The company said the earlier Human Factors evaluation focused on product and user-related feedback, while the second study added a use-related risk analysis to confirm safe and effective handling.
According to Vetter, participants in the studies found that V-OVS® next offers improved usability compared with the original V-OVS® closure, along with an enhanced user experience and a distinctive look and feel. The company also conducted evaluations of the system’s structural performance during manufacturing and handling, which it said demonstrated improved performance, intuitive handling, and a reduced likelihood of misuse.
“Our goal was to combine safety, usability, and design in a way that truly benefits the user of the system,” said Dr. Claus Feussner, Senior Vice President Development Service at Vetter. “The positive results from both usability and performance evaluations confirm that V-OVS® next delivers on these objectives.”
Vetter said industrialization of V-OVS® next remains on track, with commercialization planned for 2027. Following launch, the company said it will continue to offer both the original V-OVS® and V-OVS® next, expanding its syringe-closure portfolio. The two systems share the same contact materials and industry-standard tip cap rubber formulations, which Vetter said will allow customers to upgrade existing products or differentiate new drug offerings more easily.
